Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo

Clinical Cancer Research

Volumn 14, Issue 14, 2008, Pages 4658-4666

  Ottewell, Penelope D ^a,b   Deux, Blandine ^c   Mönkkb̈nen, Hannu ^a,d   Cross, Simon ^b   Coleman, Robert E ^a   Clezardin, Philippe ^c   Holen, Ingunn ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c INSERM   (France)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE ATROPHY; BONE METASTASIS; BREAST CANCER; BREAST TUMOR; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG DOSE SEQUENCE; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; BONE TUMOR; DRUG EFFECT; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; NUDE MOUSE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; DOXORUBICIN; FEMALE; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE;

EID: 51649118688     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1545     Document Type: Article

References (44)

1. Kominski SL, Davidson NE. A "bone" fide predictor of metastasis? Predicting breast cancer metastasis to bone. J Clin Oncol 2006;24:2227-9.
2. Green JR. Antitumor effects of bisphosphonates. Cancer 2003;97:840-7.
3. van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates, Biochem Biophys Res Commun 1999;264: 108-11.
4. Coxon FP, Helfrich MH, Van't Hof R, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000;15: 1467-76.
5. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-78.
6. Dunford JE, Thompson K, Coxon FP, et al. Structureactivity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-42.
7. Clezardin P. Anti-tumour activity of zoledronic acid. Cancer Treat Rev 2005;31 Suppl 3:1-8.
8. Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995;55: 3551-7
9. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 2000;88:2979-88.
10. Van der Pluilm G, Que I, Sijmons B, et al. Interference with microenvironmental support impairs the de novo formation of metastases in vivo. Cancer Res 2005;65: 7682-90.
11. Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003; 18:482-92.
12. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005;1042522-9.
13. Michigami T, Hiraga T, Williams PJ, et al. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 2002;75:249-58.
14. Hiraga T, Ueda A, Tamura D, et al. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int J Cancer 2003;106:973-9.
15. Hiraga T, Williams PJ, Ueda A. Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004;10:4559-67.
16. Corey E, Brown LG, Quinn JE, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003;9:295-306.
17. Gao L, Deng H, Zhao H, et al. HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood 2005; 106:4294-302.
18. Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007;99:322-30.
19. Tassone P, Forciniti S, Galea E, et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000;14:841-4.
20. Matsumoto S, Kimura S, Segawa H, et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 2005;47:31-9.
21. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005;113:364-71.
22. Neville-Webbe HL, Evans CA, Coleman RE, Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006;27:92-103
23. Kim SJ, Uehara H, Yazici S, et al. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res 2005;65:3707-15.
24. Brubaker KD, Brown LG, Vessella RL, Corey E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 2006;6:15.
25. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 1994;45:649-56.
26. Silber R, Liu LF, Israel M, et al. Metabolic activation of N acylanthracyclines precedes their interaction with DNA topoisomerase II. NCl Monogr 1987;4:111-5.
27. Woodward JK, Neville-Webbe HL, Coleman RE, Holen I. Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs 2005;16:845-54.
28. Peyruchaud O, Winding B, Pecheur I, Serre CM, Delmas P, Clezardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 2001;16:2027-34.
29. Kyle AH, Huxham LA, Baker JH, Burston HE, Minchinton Al. Tumor distribution of bromodeoxyuridinelabeled cells is strongly dose dependent. Cancer Res 2003;63:5707-11.
30. Marshman E, Ottewell PD, Potten CS, Watson AJ. Caspase activation during spontaneous and radiation-induced apoptosis in the murine intestine J Pathol 2001;195:285-92
31. Ottewell PD, Varro A, Dockray GJ. et al COOH- terminal 26-arnino acid residues of progastrin are sufficient for stimulation of mitosis in murine colonic epithelium in vivo. Am J Physiol Gastrointest Liver Physiol 2005;288:G541-9.
32. Yoneda T. Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997;99:2509-17.
33. Hiraga T, Williams PJ. Mundy GR, Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001;61:4418-24
34. Nemoto R, Satou S, Mochizuki T, Okabe K. Response of MBT-2 bladder carcinoma-induced osteolysis to various agents. Cancer 1992;69:2316-21.
35. Nemoto R, Nishijima Y, Uchida K, Koiso K. Inhibition by a new bisphosphonate (YM175) of bone resorption induced by the MBT-2 tumour of mice Br J Cancer 1993;67:893-7.
36. Pollard M, Luckert PH. Effects of dichloromethylene diphosphonate on the osteolytic and osteoplastic effects of rat prostate adenocarcinoma cells J Natl Cancer Inst 1985;75:949-54.
37. Pollard M. Luckert PH, Scheu J. Effects of diphosphonate and X-rays on bone lesions induced in rats by prostate cancer cells. Cancer 1988;61: 2027-32.
38. Nemoto R, Sato S, Nishijima Y, Miyakawa I, Koiso K. Harada M. Effects of a new bisphosphonate (AHBuBP) on osteolysis induced by human prostate cancer cells in nude mice. J Urol 1990;144:770-4.
39. Shipman CM, Vanderkerken K, Rogers MJ, et al. The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. Br J Haematol 2000;111 283-6
40. Edwards CM, Mueller G. Roelofs AJ, et al. Apomi netrade mark, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. Int J Cancer 2007;120:1657-63.
41. Peng H, Sohara Y Moats RA, et al. The activity of zoledronic acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumour cell survival and proliferation. Cancer Res 2007;67:9346-55
42. Derenne S, Amiot M, Barille S, et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment J Bone Miner Res1999;14:2048-56.
43. Saad F. New research findings on zoledronic acid survival, pain, and anti-tumour effects. Cancer Treat Rev 2007;10:1016.
44. Lipton A, Cook R, Major P Smith MR, Coleman RE Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007;12:1035-43.